Baxter International (BAX) recently announced the launch of five new injectable pharmaceutical products in the United States, which, when combined with the previous five launches announced in April 2024, marks a total of 10 U.S. injectable product launches in 2024.These new launches reinforce Baxter’s leadership in bringing high-value, specialty injectable products to market to help address critical patient needs. The launches further strengthen Baxter’s Pharamaceutical business segment.Likely Trend of BAX ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 _________________________________________________________________________________ FORM 10-Q _________________________________________________________________________________ ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to C ...

Baxter International Inc. (NYSE:BAX) Q3 2024 Earnings Conference Call November 8, 2024 8:30 AM ET Company Participants Clare Trachtman - Senior Vice President, Chief Investor Relations Officer Joe Almeida - Chairman, President and Chief Executive Officer Joel Grade - Executive Vice President and Chief Financial Officer Conference Call Participants Travis Steed - Bank of America Securities Robert Marcus - JPMorgan Pito Chickering - Deutsche Bank Vijay Kumar - Evercore ISI Joanne Wuensch - Citi Lawrence Biege ...

Baxter International Inc. (BAX) reported third-quarter 2024 adjusted earnings per share (EPS) of 80 cents, which beat the Zacks Consensus Estimate of 78 cents by 2.6%. The bottom line declined 2.4% from the year-ago quarter’s level.On a GAAP basis, the company reported EPS of 27 cents compared with $4.93 in the prior-year quarter.The company reported adjusted EPS from continuing operations, which include Medical Products & Therapies, Healthcare Systems & Technologies and Pharmaceuticals segments, of 49 cent ...

For the quarter ended September 2024, Baxter International (BAX) reported revenue of $2.7 billion, down 27.2% over the same period last year. EPS came in at $0.80, compared to $0.68 in the year-ago quarter.The reported revenue represents a surprise of -29.72% over the Zacks Consensus Estimate of $3.84 billion. With the consensus EPS estimate being $0.78, the EPS surprise was +2.56%.While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how they compare to Wal ...

Baxter International (BAX) came out with quarterly earnings of $0.80 per share, beating the Zacks Consensus Estimate of $0.78 per share. This compares to earnings of $0.68 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 2.56%. A quarter ago, it was expected that this drug and medical device maker would post earnings of $0.66 per share when it actually produced earnings of $0.68, delivering a surprise of 3.03%.Over the last fou ...

______________________ Exhibit 99.1 FOR IMMEDIATE RELEASE BAXTER REPORTS THIRD-QUARTER 2024 RESULTS • Baxter third-quarter 2024 sales totaled $3.85 billion • Third-quarter total Baxter U.S. GAAP diluted earnings per share (EPS) were $0.27 ; adjusted total Baxter diluted EPS were $0.80 , exceeding the company's previously issued guidance • Third-quarter sales from continuing operations of $2.70 billion increased 4% on both a reported and constant currency basis , reflecting growth across all segments • Third ...

Baxter International Inc. (BAX) is scheduled to release third-quarter 2024 results on Nov. 8, before the opening bell. In the last reported quarter, the company’s earnings beat the Zacks Consensus Estimate by 3.03%. BAX’s earnings beat estimates in each of the trailing four quarters, delivering an average surprise of 3.74%.Stay up-to-date with all quarterly releases: See Zacks Earnings Calendar.Q3 EstimatesCurrently, the consensus estimate for revenues is pegged at $3.84 billion, indicating an improvement o ...

In its upcoming report, Baxter International (BAX) is predicted by Wall Street analysts to post quarterly earnings of $0.78 per share, reflecting an increase of 14.7% compared to the same period last year. Revenues are forecasted to be $3.84 billion, representing a year-over-year increase of 3.6%.The consensus EPS estimate for the quarter has remained unchanged over the last 30 days. This represents how the covering analysts, as a whole, have reassessed their initial estimates during this timeframe.Ahead of ...

Investors looking for stocks in the Medical - Products sector might want to consider either Baxter International (BAX) or LeMaitre Vascular (LMAT) . But which of these two companies is the best option for those looking for undervalued stocks? Let's take a closer look.Everyone has their own methods for finding great value opportunities, but our model includes pairing an impressive grade in the Value category of our Style Scores system with a strong Zacks Rank. The Zacks Rank favors stocks with strong earning ...